Next Article in Journal
Pneumomediastinum Mimicking Congenital Pulmonary Airway Malformation
Next Article in Special Issue
Pathophysiology of Atopic Dermatitis and Psoriasis: Implications for Management in Children
Previous Article in Journal
The Importance of Oral Health in Immigrant and Refugee Children
Previous Article in Special Issue
New Cosmetic Formulation for the Treatment of Mild to Moderate Infantile Atopic Dermatitis
Open AccessReview

Biologic Treatment Options for Pediatric Psoriasis and Atopic Dermatitis

1
Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, 475 Vine St, Winston-Salem, NC 27101, USA
2
Department of Dermatology, Wake Forest School of Medicine, 475 Vine St, Winston-Salem, NC 27101, USA
3
Department of Pathology, Wake Forest School of Medicine, 475 Vine St, Winston-Salem, NC 27101, USA
4
Department of Social Sciences & Health Policy, Wake Forest School of Medicine, Winston-Salem, NC 27101, USA
5
Department of Dermatology, University of Southern Denmark, Campusvej 55, 5230 Odense, Denmark
*
Author to whom correspondence should be addressed.
Children 2019, 6(9), 103; https://doi.org/10.3390/children6090103
Received: 30 July 2019 / Revised: 27 August 2019 / Accepted: 6 September 2019 / Published: 11 September 2019
(This article belongs to the Special Issue Atopic Dermatitis and Psoriasis in Children)
Background and Objectives: Severe, recalcitrant cases of pediatric psoriasis or atopic dermatitis may necessitate treatment with biological agents; however, this may be difficult due to lack of treatment options and standardized treatment guidelines. This review evaluates the biological treatment options available, including off-label uses, and provides a basic therapeutic guideline for pediatric psoriasis and atopic dermatitis. Materials and Methods: A PubMed review of biological treatments for pediatric psoriasis and atopic dermatitis with information regarding age, efficacy, dosing, contra-indications, adverse events, and off-label treatments. Results: Currently there are three European Medicines Agency (EMA)-approved biological treatment options for pediatric psoriasis: etanercept, ustekinumab, and adalimumab. While dupilumab was recently Food and Drug Administration (FDA)- and EMA-approved for adult atopic dermatitis, it is still not yet approved for pediatric atopic dermatitis. Conclusions: Given the high morbidity associated with pediatric atopic dermatitis and psoriasis, there is a need for more treatment options. Further research and post-marketing registries are needed to extend the use of biologics into pediatric patients. View Full-Text
Keywords: children; adolescents; biologics; atopic dermatitis; psoriasis children; adolescents; biologics; atopic dermatitis; psoriasis
MDPI and ACS Style

Cline, A.; Bartos, G.J.; Strowd, L.C.; Feldman, S.R. Biologic Treatment Options for Pediatric Psoriasis and Atopic Dermatitis. Children 2019, 6, 103.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop